Full text
Earnings transcript
Read the complete earnings call transcript.
JNJ
Johnson & Johnson
$243.04
-1.08
(-0.44%)
| Exchange: | NYSE |
| Market Cap: | 585.702B |
| Shares Outstanding: | 2.922B |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Drug Manufacturers – General | |||||
| CEO: | Joaquin Duato | |||||
| Full Time Employees: | 138100 | |||||
| Address: |
| |||||
| Website: | https://www.jnj.com |
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company’s core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company’s two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 85,159,000 | 88,821,000 | 94,193,000 |
| Gross Profit | 58,606,000 | 61,350,000 | 68,558,000 |
| EBITDA | 23,320,000 | 24,781,000 | 41,055,000 |
| Operating Income | 23,409,000 | 22,149,000 | 25,596,000 |
| Net Income | 35,153,000 | 14,066,000 | 26,804,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 167,558,000 | 180,104,000 | 17,500 |
| Total Liabilities | 98,784,000 | 108,614,000 | 3,000 |
| Total Stockholders Equity | 68,774,000 | 71,490,000 | 14,500 |
| Total Debt | 29,332,000 | 36,634,000 | 0 |
| Cash and Cash Equivalents | 21,859,000 | 24,105,000 | 200 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 22,791,000 | 24,266,000 | 24,530,000 |
| Capital Expenditure | -4,543,000 | -4,424,000 | -4,832,000 |
| Free Cash Flow | 18,248,000 | 19,842,000 | 19,698,000 |
| Net Income | 13,326,000 | 14,066,000 | 26,804,000 |
| Net Change in Cash | 7,732,000 | 2,246,000 | 0 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 124,152,324.162 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 130,219,745.409 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 127,414,600 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 37,616,563.875 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 39,454,914.792 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 38,604,991.666 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 39,248,779.066 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 41,762,139.131 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 40,600,132.816 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 31,274,677.308 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 32,803,095.265 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 32,096,463.165 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 16.710 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 17.190 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 16.160 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 6 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: Johnson & Johnson reported strong financial results in Q2 2025, as highlighted in the earnings call transcript, with key metrics such as revenue and net income showing consistent growth. This performance aligns with historical data from income statements, reflecting sustained profitability and operational efficiency.
- Diversified Portfolio and Innovation: The earnings call emphasized JNJ's diversified portfolio across pharmaceuticals, medical devices, and consumer health, driving growth through innovation. Revenue product segments indicate balanced contributions across categories, reducing reliance on any single segment.
- Strong Cash Flow and Dividend Yield: Cash flow statements show healthy net cash provided by operating activities and free cash flow, supporting financial stability. The dividend yield (from key metrics TTM) remains attractive for income-focused investors, reinforcing JNJ's position as a reliable dividend stock.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates JNJ intrinsic value between $120.18 – $187.13 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about JNJ valuation
Is Johnson & Johnson (JNJ) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Johnson & Johnson (JNJ) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is JNJ a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether JNJ trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is JNJ’s P/E ratio?
You can see JNJ’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for JNJ?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is JNJ a good long-term investment?
Whether JNJ fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
JNJ
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.44
Trading Metrics:
| Open: | 245.11 | Previous Close: | 244.12 | |
| Day Low: | 242 | Day High: | 247.21 | |
| Year Low: | 141.5 | Year High: | 251.71 | |
| Price Avg 50: | 238.9 | Price Avg 200: | 198.41 | |
| Volume: | 5.283M | Average Volume: | 8.601M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeJNJ full analysis
Below is a comprehensive stock analysis video transcript for Johnson & Johnson (JNJ). I've structured it as a detailed, engaging, and conversational piece with all the required visual markers and sections. This transcript is designed for a long-form YouTube video, providing substantial insights for long-term investors. --- **** Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive stock analysis of a true heavyweight in the healthcare space—Johnson & Johnson, ticker symbol JNJ. If you’re looking…
